J&J beats Wall Street estimates
Johnson & Johnson beat second-quarter profit and revenue estimates, boosted by strong sales of its drugs, including cancer treatment Darzalex and psoriasis blockbuster Stelara. The drug and device maker’s shares rose 1.4 per cent to $153.15.
ENTRADAS POPULARES
Portugal declares risk as wildfires hit the north of the country
septiembre 17, 2024
UK to appoint nature envoy
septiembre 17, 2024
Death tolls rises as Central Europe floods
septiembre 17, 2024
‘The Twelve’, a drama starring Sam Neill, has been renewed for a third season
septiembre 17, 2024
TRANSMISIÓN EN VIVO